MediCA klinika has acquired Lieporiu Seimos Gydytoju Centras
MediCA klinika, the largest private clinics chain in Lithuania, has acquired Lieporiu Seimos Gydytoju Centras, a private primary care clinic in Siauliai city.
MediCA klinika operates 31 clinics in 16 cities, with revenues of approximately US$35 million. It belongs to CGP Management, a privately owned holding company which also owns the leading pharmacy chain in Lithuania. This acquisition will allow MediCA klinika to expand its market coverage in the country.
Lieporiu Seimos Gydytoju Centra is the largest private clinic in Siauliai city, the fourth largest city of Lithuania, with over 5,000 registered patients.
Oaklins’ team in Lithuania acted as advisor for the buyer throughout the acquisition process, from searching for add-on acquisition targets in Lithuania until final completion.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more